Published in

Royal Society of Chemistry, Biomaterials Science, 10(2), p. 1332-1337, 2014

DOI: 10.1039/c4bm00156g

Links

Tools

Export citation

Search in Google Scholar

Graphene oxide modified with aptamer-conjugated gold nanoparticles and heparin: A potent targeted anticoagulant

Journal article published in 2014 by Yi-Heng So, Huan-Tsung Chang ORCID, Wei-Jane Chiu, Chih-Ching Huang ORCID
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Graphene oxide (GO) modified with 29-mer thrombin-binding-aptamer-conjugated gold nanoparticles (TBA29–Au NPs/GO) can synergistically inhibit the thrombin-mediated cleavage of fibrinogen to fibrin. To further improve anticoagulation efficiency in human plasma, TBA29–Au NPs/heparin/GO has been prepared from TBA29–Au NPs/GO and heparin that can also bind thrombin. The dose-dependence of thrombin clotting time (TCT) delay caused by TBA29–Au NPs/heparin/GO is 21.4, 17.0 and >100 times higher than that caused by the TBA29–Au NPs, TBA29–Au NPs/GO and commercially available drugs (heparin, argatroban, hirudin or warfarin), respectively.